Important Caveats About the Research Several important limitations should be acknowledged when reviewing the EpitalON literature: The majority of published studies originate from Khavinson's research group or closely affiliated laboratories Independent replication outside Russia has been limited, though the 2025 Biogerontology study represents a notable exception Human clinical data remains sparse, consisting mainly of small studies from one research group Most research has used injectable EpitalON, not oral formulations The peptide is not approved as a medicine in the UK, EU, or US How EpitalON Capsules Are Typically Taken Research Protocol Context The research literature commonly references cycles of 10-20 days at 5-10mg daily, repeated periodically (such as once or twice yearly)
( )
Simes AP, Duarte JA, Agasse F, Canas PM, Tom AR, Agostinho P, et al
Published this week in The Lancet Diabetes & Endocrinology , the research findings looked at 11 large-scale trials investigating seven medications in the GLP-1 receptor agonist class, including semaglutide (sold as Ozempic or Wegovy), dulaglutide (sold as Trulicity), and liraglutide (sold as Victoza)
The study was supported by a grant from The Faroese Research Council
